Global Blood Therapeutics (GBT) is a clinical stage biopharmaceutical company developing novel therapeutics to treat grievous, non-malignant blood-based conditions with significant unmet needs. 

GBT440, the company’s lead drug candidate, is a potential once daily oral prophylactic therapy for patients with sickle cell disease (SCD), which has the potential to halt red blood cell sickling, disease progression, and could fundamentally transform the lives of SCD patients.  A Phase I/II study is ongoing.

In addition to GBT440, the company is currently identifying small molecule leads for an orally administered prophylactic therapy for HAE.  Additionally, GBT scientists are developing novel hemoglobin modifiers for pulmonary disorders in which increased oxygen delivery is needed (e.g. acute respiratory distress syndrome).

GBT’s R&D programs are discovered internally based on combining our extensive expertise and capabilities in blood biology, medicinal chemistry and structural biology.

GBT was launched in 2012 with funding from leading healthcare investor Third Rock Ventures. In December 2014, the company completed a $48 million Series B financing including investments from Wellington Management Company LLP, RA Capital, Deerfield Management, Sabby Capital, Perceptive Life Sciences, an affiliate of Cowen Group and one undisclosed blue chip public investment fund.